Argenx bid for Vyvgart label expansion undergoes FDA priority review

argenx-bid-for-vyvgart-label-expansion-undergoes-fda-priority-review
Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

Argenx (ARGX) announced on Tuesday that the U.S. FDA has granted priority review for its marketing application aimed at widening the approvability of Vyvgart, its blockbuster treatment for a rare autoimmune disease known as generalized myasthenia gravis.

The company stated